Resistance to antimicrobial agents: An update

Pharmacotherapy

Volumn 24, Issue 12 II, 2004, Pages

  Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial resistance; Bacterial pathogens; Carbapenems; Cephalosporins; Fluoroquinolones; Nosocomial infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CARBAPENEM; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; IMIPENEM; LEVOFLOXACIN; METICILLIN; METRONIDAZOLE; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG APPROVAL; DRUG COST; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 9644295687     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.18.203S.52236     Document Type: Conference Paper

References (82)

1. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the western Pacific region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32:S114-32.
2. Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002;43:239-43.
3. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32:S133-45.
4. Winokur PL, Canton R, Casellas J-M, Legakis N. Variations in the prevalence of strains expressing and extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32:S94-103.
5. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32:S81-93.
6. Weinstein RA. Nosocomial infection update. Emerg Infect Dis 1998;4:416-20.
7. Palumbi SR. Humans as the world's greatest evolutionary force. Science 2001;293:1786-90.
8. Centers for Disease Control and Prevention. Campaign to prevent antimicrobial resistance in healthcare settings: why a campaign? Available from http://www.cdc.gov/drugresistance/healthcare/problem.htm. Accessed June 1, 2004.
9. National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-98.
10. Spellberg B, Powers JH, Brass EP, Miller LO, Edwards JE. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004;38:1279-86.
11. Avenus Pharmaceuticals Inc. First-in-class antibiotic to treat mild to moderate community-acquired respiratory tract infections. Press release. Available from http://www.aventis.com/main/page.asp? pageid= 51353720040331233509&lang=en. Accessed August 3, 2004.
12. Larkin M. Antibiotic resistance now deemed a "public health crisis." Available from http://www.lemmo.com/side_navi/news/news0503. html#antibiotic. Accessed October 6, 2004.
13. Centers for Disease Control and Prevention. Slide presentation: campaign to prevent antimicrobial resistance, slide 9. Available from http://www.cdc.gov/drugresistance/healthcare/ha/Haslideset_clean.ppt. Accessed June 22, 2004.
14. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003;24:251-6.
15. Morris JG, Sahy DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-9.
16. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34:922-9.
17. Wegener HC, Aarestrup FM, Jensen LB, Hammerum AM, Bager F. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerg Infect Dis 1999;5:329-35.
18. McDonald LC, Kuehnert MJ, Tenover FC, Jarvis WR. Vancomycin-resistant enterococci outside the health care setting: prevalence, sources, and public health implications. Emerg Infect Dis 1997;3:311-17.
19. Carmelli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002;8:802-7.
20. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001;7:183-7.
21. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925-32.
22. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-82.
23. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003;36:131-9.
24. Centers for Disease Control and Prevention. MRSA - methicillin resistant Staphylococcus aureus fact sheet. Available from http://www.cdc.gov/nciod/dbmd/ hip/Aresist/mrsafaq.htm. Accessed August 5, 2004.
25. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-22.
26. Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002;43:225-32.
27. Salmenlinna S, Lyytikäinen O, Vuopio-Varkila J. Community-acquired methicillin-resistant Staphylococcus aureus, Finland. Emerg Infect Dis 2002;8:602-7.
28. McKinnon PM, Swiderski LM, Rybak MJ. Evaluation of potential treatment options for community-onset Staphylococcus aureus (C-SA) infections. Presented at the 41st annual meeting of the Infectious Diseases Society of America, San Diego, CA, October 9-12, 2003.
29. Shopsin B, Mathema B, Martinez J, et al. Prevalence of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in the community. J Infect Dis 2000;182;359-62.
30. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST surveillance program (1998-2002). Clin Infect Dis 2003;36:963-70.
31. Centers for Disease Control and Prevention. Drug-resistant Streptococcus aureus disease technical information. Available from http://www.cdc.gov/nciod/ dbmd/diseaseinfo/drugresisstreppneumo_t.htm. Accessed August 5, 2004.
32. Baddour LM, Hicks DV, Tayidi MM, et al. Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital. Microb Drug Resist 1995;1:219-22.
33. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β-lactamase-producing organisms. Clin Infect Dis 1995;21:1107-13.
34. Krcmery V Jr, Spanik S, Krupova I, et al. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study. Chemotherapy 1998;10:320-5.
35. Lee SO, Kim YS, Kim BN, Kim MN, Woo JH, Ryu J. Impact of previous use of antibiotics on development of resistance to extended-spectrum cephalosporins in patients with Enterobacter bacteremia. Eur J Clin Microbiol Infect Dis 2002;21:577-81.
36. D'Agata EM, Venkataraman L, DeGirolami P, et al. Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med 1999;27:1090-5.
37. Raymond DP, Pelletier SJ, Crabtree TD, Evans HL, Pruett TL, Sawyer RG. Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003;31:1035-41.
38. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185-90.
39. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-20.
40. Sahm DF, Critchley IA, Kelly LJ, et al. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 2001;45:267-74.
41. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2003;35:1505-11.
42. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1-9.
43. Neuhauser MM, Weinstein RA, Rydman R, Danzinger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: implications for fluoroquinolone dose. JAMA 2003;289:885-8.
44. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643-8.
45. Mutnik AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-6.
46. Bhavnani SM, Callen WA, Forrest A, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health-Syst Pharm 2003;60:1962-70.
47. Centers for Disease Control and Prevention. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999. Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5037a2.htm. Accessed August 6, 2004.
48. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc 1999;74:187-95.
49. Sanders CC. Cefepime, the next generation: the reasons and rationale behind its development. Drugs Today 1995;31:221-5.
50. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States: national nosocomial infections surveillance system. J Infect Dis 1994;170:1622-5.
51. Muller A, Lopez-Lozano JM, Bertrand X, Talon D. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 2004;54:173-7.
52. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
53. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance: report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992;15(2suppl 1):37S-42.
54. Conus P, Francioli P. Relationship between ceftriaxone use and resistance of Enterobacter species. Clin Pharm Ther 1992;17:303-5.
55. Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA, Jones RN. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC programme. Diagn Microbiol Infect Dis 2001;39:125-7.
56. Andrade SS, Jones RN, Gales AC, Sader HS. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY antimicrobial surveillance program (1997-2001). J Antimicrob Chemother 2003;52:140-1.
57. Low DE. Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin Infect Dis 2001;33(suppl 3):S206-13.
58. Tenover FC. Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin Infect Dis 2001; 33(suppl 3):S108-15.
59. Levy SB. Antibiotic resistance: consequences of inaction. Clin Infect Dis 2001;33(suppl 3):S124-9.
60. van den Bogaard AE, Stobberingh EE. Epidemiology of resistance to antibiotics: links between animals and humans. IntJ Antimicrob Agents 2000;14:327-35.
61. Levy SB. Antibacterial household products: cause for concern. Emerg Infect Dis 2001;7:512-15.
62. Melano R, Corso A, Petroni A, et al. Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum β-lactamases in a Klebsiella pneumoniae clinical strain isolated in Argentina. J Antimicrob Chemother 2003;52:36-42.
63. Conceiçāo T, Faria N, Lito L, et al. Diversity of chromosomal AmpC β-lactamases from Enterobacter cloacae isolates in a Portuguese hospital. Fed Eur Microbiol Soc Microbiol Lett 2004;230:197-202.
64. Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 2004;48:716-20.
65. Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004;42:269-75.
66. IMP allelic variants carried by gene cassettes of different phylogeny. Antimicrob Agents Chemother 2000;44:1229-35.
67. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-62.
68. Palmer SM, Kang SL, Cappelletty DM, Rybak MJ. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and β-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 1995;39:1764-71.
69. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001;7:337-41.
70. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 2002;34:1613-20.
71. Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004;48:1295-9.
72. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-8.
73. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:1433-7.
74. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
75. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001;175:264-7.
76. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36:1418-23.
77. Toubes E, Singh K, Yin D, et al. Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference? Clin Infect Dis 2003;36:724-30.
78. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
79. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002;34:1600-6.
80. Centers for Disease Control and Prevention. 12 steps to prevent antimicrobial resistance among hospitalized adults. Available from http://www.cdc.gov/drugresistance/healthcare/ha/12steps_HA.htm. Accessed June 17, 2004.
81. McGowan JE Jr, Gerding DN. Does antibiotic restriction prevent resistance? N Horiz 1996;4:370-6.
82. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505-11.